Navigation Links
Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring
Date:4/4/2011

NEW ORLEANS, April 4, 2011 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) announced additional data that showed that overweight and obese patients treated with Contrave® (naltrexone sustained release (SR)/bupropion SR) maintained normal 24-hour circadian patterns over one year of treatment.  These data were from the ambulatory blood pressure monitoring (ABPM) sub-study of the COR-II trial that also showed weight loss and improvements in markers of cardiometabolic risk.  Data were presented at the 60th Annual Scientific Session of the American College of Cardiology (ACC) taking place in New Orleans.

"The observation that patients in this sub-study maintained normal circadian variation of blood pressure may be particularly relevant since a loss of the nocturnal lowering in blood pressure may predict a poor cardiovascular outcome," said Jorge Plutzky, M.D., Director of the Vascular Disease Prevention Program at Brigham and Women's Hospital.

Additional results showed Week 52 weight loss of 7.5% for subjects in the sub-study on Contrave as compared to 2.5% for subjects on placebo (P<0.001) and improvements, at Week 56, in waist circumference (-7.5cm vs. -2.3 cm; P<0.001), hs-CRP (-40.7% vs. -2.4%; P<0.01) and HDL-C (+4.4mg/dL vs. -0.6mg/dL; P<0.01) based on LOCF analyses.  

Study Design

The COR-II ABPM sub-study enrolled 182 of the 1496 subjects from the main trial, at nine U.S. sites.  Monitoring of ambulatory blood pressure in the sub-study was initiated prior to the intake of study drug and other morning medications and completed approximately 24-hours later at three time points during the study: baseline, Week 24 and Week 52. COR-II is one of the four Phase 3 trials supporting Orexigen's New Drug Application for Contrave.

About the Contrave Clinical Development Program


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society
2. Orexigen® Therapeutics Schedules November 3, 2010 Webcast Discussion of Financial Results for the Third Quarter Ended September 30, 2010
3. Orexigen® Therapeutics to Present at JP Morgan Healthcare Conference
4. Orexigen® Therapeutics Announces Corporate Realignment
5. Orexigen® Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
6. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
7. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
8. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
9. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
10. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
11. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... (PRWEB) October 22, 2014 Currently ... Sartorius, A & D Weighing, Rice Lake, and ... Semi-Micro Balance . The Sartorius CPA Semi-Micro Balance ... affordable high-quality, precise, and user-friendly laboratory balance. , ... laboratory equipment, their laboratory balances are well known ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 According ... Market by Service Type (Consulting, Integration, Deployment & ... by Deployment Model (Public, Private, Others (Hybrid & ... MarketsandMarkets, defines and segments the Cloud Professional Services ... and forecasting of revenues. It also identifies the ...
(Date:10/22/2014)... 22, 2014 Nuvilex, Inc. (OTCQB: NVLX) – ... people worldwide are living with diabetes, with  that number ... The global market for diabetes treatments is approximately $500 ... worldwide died from pancreatic cancer.  Pancreatic cancer is the ... in the United States , and ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 The ... (Medication Dispensing Systems, Packaging and Labeling Systems, Table-top ... Automation) - Global Forecasts & Trends to 2019” ... and opportunities in North America, Europe, Asia-Pacific, and ... 101 market tables and 30 figures spread through ...
Breaking Biology Technology:Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4
... has announced the formation of a Medical Advisory Council ... (MiCK) assay for apoptosis , a new assay designed ... patients. DiaTech has introduced this technology for individual patient ... companies in validating new drugs that may be more ...
... 2011  Rhythm announced today that Lex Van der Ploeg, ... Dr. Van der Ploeg brings to Rhythm more than ... diseases, and other therapeutic areas. "Lex has ... metabolic pathways we are targeting with our ghrelin and ...
... mystery of prematurely dead cell phone and laptop batteries may ... energy grid according to Drexel researcher Dr. Yury Gogotsi. In ... Science , Gogotsi, who is the head of the ... of performance measurement for energy storage devices that are as ...
Cached Biology Technology:DiaTech Life Sciences Announces Medical Advisory Board 2DiaTech Life Sciences Announces Medical Advisory Board 3Rhythm Names Lex Van der Ploeg Chief Scientific Officer 2Drexel expert: Efficiency metrics for energy storage devices need standardization 2
(Date:10/25/2014)... , Oct. 22, 2014 This report covers ... relatively new space in heavy pursuit of research due ... to miRNAs compared to other RNA components. miRNA,s non-coding ... a novel candidate for use as a biomarker for ... miRNA-based microarrays and diagnostics for the advancement in therapeutic ...
(Date:10/22/2014)... , Oct. 20, 2014 The Nano-Bio ... States Air Force Research Laboratory (AFRL), has chosen a ... (AzCIM) at the University of Arizona College of Medicine ... funding.  The AzCIM project,s goal is to assess different ... collect different volumes of sweat under a variety of ...
(Date:10/18/2014)... 2014 Psychological stress and stress-related psychiatric disorders are ... but the molecular mechanisms underlying this relation ... to the development of targeted preventive strategies ... devastating diseases. This work is presented at ... Berlin., Now an international group of researchers ...
Breaking Biology News(10 mins):MicroRNA: An Insight to miRNA-based microarrays, diagnostics and therapeutics Overview, Cambridge Healthtech Advisors 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 3Researchers find why depression and aging linked to increased disease risk 2
... from an observational study by researchers at the University ... 65 and 80 years of age who received treatment ... than men who did not receive treatment. The study ... the Journal of the American Medical Association. , Thanks ...
... possible new cancer drug suggests that it may prove ... chemotherapeutic drugs. , Dr David Huang, Dr Andrew Roberts, ... research divisions have been assessing the potential of a ... company, Abbott. , Under normal circumstances, human ...
... to light is missing in humans, researchers have discovered. , ... amphibians have two versions of this photoreceptor, mammals, including humans, ... Public Library of Science journal PLoS Biology ?reveal how our ... other vertebrates and fits with the suggestion that early mammals ...
Cached Biology News:Older men treated for early prostate cancer live longer than those who are not 2Hope for a more effective and less toxic cancer drug 2Does missing gene point to nocturnal existence for early mammals? 2
Reacts with the 80 kDa fragment of the M-chain of human merosin....
ICAD / DFF45 (NT) Affinity Purified Polyclonal Antibody...
... polyclonal to ZFP91 ( Abpromise ... Antigen: Synthetic peptide derived ... human ZFP91. (Note: the amino ... Entrez Gene ID: ...
AANAT [Arylalkylamine N-acetyltransferase; EC 2.3.1.87]...
Biology Products: